MDCT focuses on AI medical imaging, pioneering a 12mm disposable dual-lens image fusion colorectal endoscope. It displays three images simultaneously and uses deep learning to annotate lesions in real time, increasing early cancer detection rates by 40%. The disposable nature of the consumables avoids cross-infection and saves on expensive cleaning, making it ideal for increasingly stringent infection control measures. The product uses recyclable materials, reducing carbon emissions by 25% per endoscope, complying with ESG sustainability standards. The team spans medical device design, AI algorithms, and clinical physicians. The first round of clinical trials is underway at Tri-Service General Hospital, and FDA 510(k) filing and collection are initiating. All six biomarker tests have been passed, and the company is pursuing development in both the human and veterinary markets.